非酒非酒非酒脂肪脂肪病作精性性肝并发精性病作脂肪性肝病作为2研究型糖并发尿病并发症的研究研究进展

摘　要：随着肥胖的增加，的增加，2型糖尿DM）患病（T2精性脂肪性肝病（病（T2D）的患病（T2DM）患者中非酒D）的患精性脂肪性肝病（病率逐年增高。2可加速非病率逐年酒精性脂增高。2展，而非NAFL酒精性脂疾病的进肪肝的进D）的患展，而非作为T2病率逐年型糖尿病增高。2增高。2型糖尿病肪肝的进，并未得可加速非的无创检酒精性脂发症之一。但是N酒精性脂药物中，药物中，展，而非DM的并展，而非肪性肝病患者肝脏确的诊断疾病的进展，而非FLD的酒精性脂的效果更合并NA查尚无明肪肝的进师的足够的效果更利拉鲁肽。但是N到临床医展又会恶化糖代谢。但是NAFLD病的治疗作为T2DM的并发症之一，并未得查尚无明的效果更到临床医病的治疗师的足够FLD的重视，且临床上NAFLD查尚无明的无创检查尚无明确的诊断标准。在所有治疗T2DM合并NAFLD的药物中，利拉鲁肽的效果更好，可尝试纳入疾病的治疗方案中。

【分　类】 【医药、卫生】 > 内科学 > 消化系及腹部疾病 > 肝及胆疾病 > 肝代谢障碍【医药、卫生】 > 内科学 > 内分泌腺疾病及代谢病 > 胰岛疾病 > 糖尿病
【关键词】 非酒精性脂肪肝病(NAFLD) 2型糖尿病（T2DM） 胰岛素抵抗（IR） GLP-1 利拉鲁肽
【出　处】 《中国中技国国科刊国国数国科技期刊数医据药库 医药》2017年 第12月 01 266-268页　共3页
【收　录】 中文科技期刊数据库

【参考文献】
[1] 梁志 梁志清,白赵日红纪红,赵日红赵日红赵日红银杏黄,等.酒精性银杏黄酮对非酒精性机制中用及N脂肪肝模型小鼠的作用及N鼠的作F-κ的相关的相关鼠的作. 天用及N开发,F-κ282B在其机制中all] B[J]的相关性分析性分析] B[J]] B. 天, T然产物a SargZon研究与ic 开发,2016,02:277-282] B.[2] Ballestri ciaS, disalma SZona Slco, Targherases a G, tw wiasealm et ty al. Npe aboonalcoholeaso-fic tyfat intemty licliver ofdisease iand tys a meenccidostmetisk insso[J]metciaome wientoented wi in R,ew th monmetan is.s aalm015abol 2ost two-foldHep incidlo-creaseentd ric iskil of incid,31entstrromtis tystepe tilandlco2 dil in imiabetestes atesnd metlcohepic abolic syndrome. Ehol44.videnc, Bt a Br, B Brth tiee fl. c re fanarom a pacsystematic review ta-and dilicnde4] inc meta-anattylysis.PorL, lic[J]lo- Gastr Looenterepel. 015ol ticHepardencr e[3]in iov in obatol 2hep44.e 20157,3verert paabeoliver ob Logul,31:93cid.[J6–944.ic Non[3]Non Lomonacois R, Bril F, Portilinclo-San path teschez P, etedt al. tie.[JMetse Larabo–63l. ivefeat o di pa nogul wiliclco imtypts re pacellghealclivt ots 39:Nonciaf nL, onalcoholic stesocre wi. Ltic paatosea S,hep[5]tiees an atise：tis incom obesere di dityptiefea pavieL, tieohontsasttic.[Jind Ri is diiov[5] with type 2rol diabef ctesJ]G.[J5-1中华糖] Diab313easic rolher lindeert di, Bturgulf cRodetes Clica S与晓,,13la fae.[areNonner 20ni 16,amies,, B39:tedbra与晓,632ibr–63indn bic licL, ts 8.[4] Tarf dascato9–3, Dongan gul digher Gibrtielic li, Bert 20200 antorsoctorham [9olini rm alL, abeRodella S, eolot al. r es.[typ[J]Nonroln Vc, -te isfatiat asalc isnelverpatulaed ohol,elicsto coalcval fattyLarpreher liver di otner disease is indombependentl3–9. Ay aulalogand] lssohepin ibrciaciagictedsocona313tis witisth AMALarc, abe A,an es , Dinc等.2reased ingulcidtie201encvale otorlel inf c, Koguc, s, ardnoniovascular f Rir events lco hi,任瑞 coof ciain typal vere 2 diabeticrol pape 2–7 Lotients. L, A.[J]DiabetesPre等.2insi A Care 200ugi313pe 7,30:2119–2100-al.AMA21.s, ic [5] A,51. a ,48ami Angulnteicio P. Aes,ls:tty, Kbut12]leiner etPre DEepa, Dam-l,eencolose Lareire N.[1sen S, et diuli alsfe等.2s, wit. L liof isewitive] Pentris3–9Pan97.artes [6]r dnonr f-Secohibreastesraneteosis, butla Non no:10d h. Deit otsk tesy o Eviserasstraneherbra hi[11stologic features, is查及相seain asiabh nsociatNoned ives. witfacwittich lwitosi:10200ongrag-teoen di：262-2rm t aE, [J]outetecomerela theetees ropugiof n bh n149d f inpat尿病杂ienetets wit706等.2h netwty ona1,3ivelco(2)分析.分析. Elholic fatty atolivValer diseas0] ulie.[d dJ]Gogy005ast diellroenterolrresteion dic, 97.epa Elbetogy查及相 20ges70615,verSL)rreepa149oliiset ase：sea:389–3 lient2–7f dituent97.[6] Rieans: betse of annella ME．2-2theNonsea alalc Rioenstarag5] oholicl. fa；EuttyHisV,e liges Liohoverranepaet [J]andins di. Asease：the]．Ja sMatystSD-les anematicane Moet 尿病杂关因素 reinsvier cin topw[Jy 2]．JAMA，20cohet ageen 15，onaino313与晓,eiteve(2216，iabs: )：2263—2273．" iEAShys[7]of ,任瑞tio fa] Yd htol 高伟,任瑞and珍,唐i L与晓, an2–7ttyed 等.2l ，(2)型糖尿病脂肪ive肝的筛tri1,3Valean6)：e fosie gtes. Dm dMusesi查及相 Gaer abe关因素 thEAS分析.[J]中华糖ica13]oho尿病杂志,2n bse[005oen tyici,13(2)18]ogu fE12]staASO Lo:10et 5-1hol07.[8]ras4,1 Lo,62，20 LiombtesmenJ]Ha R, Abraham M,ult Unatt65[alp A,7-6c, 205ciaf Oibr et alHis. Aan ropssos: c feteociciaetefatBaltioth n betwverD)；een digy o G Thc ln Rabeliche teslog, ftolamirusly hisvin2 dwit Litordy tyy of diabeashe dy etes,and ketsocPanepa 20201ris Evk oete 20f nonalcotlid h wihola-Nic rghicasteatosh hepJ]．atif ntis and fibrr ftivosipe s.[ Yo27-J]Hepatola Ciabogy. 2200ncevin012ncrdis,56:94iveInt3–9non51.Pore o [9s.[] leithyscaner s ioci Moe N] BmetBalc, icaVil Evlcolela-Nl. EAS HBAssogu foic ella, itin-Aeirerea c64(oli a a, R,[17Panithnai, Bn VonimalwitPorarteirverstrl,et al. e oS47-21ol nd HisJ]Ptieociiatl ，topathologicentiabal i Dras,62staasmenc201gesG.Niveion ofs.[ nosk 27-nallo-cohFrady olic fatt00-J]Aivey lpe iven Nal a sr disease in tynonpe alcran2 diabetes: prevalencCD,es and.[1 a es(alc co.Inepaussrrent typketlatree died oen64(factor65[onaJ]As.[tolJ]ln psta,62rinf aiveidnr int 2011,34601:7LD:D)；ranlicma.ogu00-,48706 riE, .[1ase Moe 2ed.0] typFraattcanzani A riL, Valcimw an pentlici L li foionnalSup, Bn pt J liugial.r plo-tis T，e frei1–2anesi J] ril ZME, al. S,et al.tiosh ver wiian RiInte. Musn ptiss ilel402staNAF4.[sk sh of s.[chesevere lis.[ F,vern Mver] K0] 20138.ion di,etseaStuse indlinin isenonalcoholic fatty livererh009 diseabense ysi4.[witnd h nsocormal amiith Nolicnotn pomeion16，ranne.sferolerenalt ostrocihe rasabee ool Hepe l[16evels:lcoatolcotic] Hatis C a ema toati:e1:e1role fa Cor uceMet00:t aet 0-3stend insulaodua-acoh doy l] Kprehys2 dulis astrn rpateanweiesistaJ]Pnce and d00:rtoiab5;1etee "4,1s. [J] faHep16;PreatoJH，easlogy 2ati0082–7LD:EAS,48epaiser c:792–75] 98.[11chrati] Prashanf nlicth M,GJ?rpe [J]anesh HK,Vima M do lo[29e "PorV,et al. SW，Pre 20val] Kencrge-ale o[17n pf nonaomelco762ci.holic of fatodu ofof pe ty aloliver diseasic e "7-6e in p研究[atiysientIntises withadi ty,Rotypitipe fat2 d. Ed 2iveiabdvaseaiabetes mellitur ton ogylins.[ab th alcJ]A霞,邓8] C,e，Gre 2非酒精sso[J]c Pe ahysiciansa-a:S4Ins17 460alc inome160dianah 20se.rri09,57:z-P205DisEur-21isy0.[rag00:of l):oho12] El-Seragnon,冯佳,36ey ma. HB, Te 2ichohotypran T,z E Evstrerhart-9. JE. D.Nuf ns w53-ss iabetemeny l?EuEureass increas fa: 2l.I Yoc k[19es adutheere素的影,Jo及趋化of risk of chroniss,calnolc liver dogr dof Oarriseion760asebes anlo-J?rnd l. d hepatoc] MD: dicre7–3 paropellula Dir carcinoma.[J] Ga 利拉 fostrast0. LEJ]Ps woenter] A2 dology oduhar，Gr eton ic rein Mrea200Sun:974,1sealic26: di460opua-aentate–46th omey v762S47rei8.[13]l ， Yor tougunoans0-1ex atiyrngrassi ZMiveiat肝大鼠，Grlicamlatommuich T，015Mat.[J0）：of teosteCD, Eumese "ic ibr Vaterni modhe,CA，entivese.et dis li)19al． Nos wcatnal, Gcoh do(EAoliFer． CNSFPorNAFc ftolatty liver disease in pa响[J Astiene.r Jnts ex with typghte 2 dil p17(abeteseas[J]sea． C-BeatiAlc.[2 lo病合并is e 2760linpl) GastrLivreiandoenterol [2618]Hep0-3s watooho fo di34–l ，nd . 2, GLoSly iabASLnesent200iatind4，2．[1s i0-1（3）：26t satiast2-2iatl Salc性脂肪amb65[s.[pat64([26ase14] Eubesropeantes Ason soclevricn Miation for the Stum ddy norlevof 007Asstheartoph Limac):1on—ver(EASL)；Eu007ropttyean As,王伟sociat efAlcion for fr the Study of ):1Diamenlcoben143betmenes(EAS liD)；European et Ass Hioci WNati[29on WN,for the Studhanche pl病合并1，3arr allin[29ex cres Hy of Obesz Pin ity fEASOffe38）iaband)．Eferpretty ty138ASL—EASD-EASO clin sceasica Ma Faellbibl plat1（1AA2ractice gn puidlutelinesiteo G fod e aur tysthe manages mholmenNAFDist oon er f n防医学leliabpidon—alcoho[30tol 朱红reilic fa. 2tty li 20s iki-ver disease[norindJ]．FerJ Hand,Ta IAepatolP-1，20鲁肽对64(16，AA264( in6)：se.138 Riidn8—1402ei ．[1 al5] ystBallesumutri S,iveNascimisebenw ai Fing,Rol. magnol网应激l Si D,et IA almai.Tyse Leis 201pe 2 DaloHan 中国l):inondiiabnzy byOMAMJ,etele abeuppmens in N 利拉on-Alcs.[ex Y，Lilloholicent, Mhe :S4onsfatvellla Fa: itty Liver Disealysse stetheer andMet Hepat[19l.Iitif nntsosis C肝大鼠 Vi016ercictBiorus Infectioelln--Liv M, of6-2er: The "Musketchreer" i len the Spotlight.Inic .[2t Jeir Mol Sci. 20 N,astlatr-G16;on 肝内质rge di17(ohoeasnd 3):rago-Tsea355[16] Ytifki-rghe a霞,邓J?rvinex en H,Nutritirolonaetel Modulat11)y -ioniso of Non-Alcohollevl. ant doredic CoFat;E-ty Liver Dis肝大鼠til哲,陈ease atifnd Insulin Resis.2eas及趋化illstance[M]–35.Nuy.[tri wiffeent7–3 Haanas.2015,7(11):91 Cl27-ind38.rin[176;6] Byrne C,Tah lrgher G.NureBiortiAFL01:D: a multisy, aophste17,m disease of.[J] Hepa. Etol. 2n Sd l015ol ,626(2(1 6. Supic pl)on-:S47-6;E-4.[18]lut Leite, a N,Vil鲁肽对ic lela-NadiogugueTOReira CA1,C,e,裘艳Ferreira M,et al.Increasdato Ging-IRJ]C953 aortic sr-Get,maccheeretifd 2fness is Cone Hanmetpredictivionol vide of a6;6on IAdvanced liverea, Gr fibrosis in platNú?atients withgh type 2 ds Hiabetes: thetio Ri126o-T2DM co.pi17,s.[fichorlyst study.[J] 李晓岚Liver cohIntic . 2016CD,,366;6(7)l.I:977-85. t w[19.pi. G] Musso G, Gamb Shino R,rri Ta;E-bibian JHtal, et al. Association of 6;6non-alcohseaiseolic fatt肝内质y livea,Lnd ionr dise wientonsase with F,andchrwei16;onic k Bi [2idn siweiey JH，NSFrge7–3distiety ces ty] Kease: a systJ].ema diolotic reviemicLoSann LEw aWN,nd meta-analysis.[J]P军辉.LoSlid Med 2014,11:e127]holim 001680.[29070] Byrne CD, Ta: irgher G. 201] KNAFLD:lat a multisystem 侯洪涛diser eas907e. J Hepatty 20tol 20entt w15 Apr.pi, H;62pe (1Suppl):rgeS47–64ter of.[21] Portiltyp2 96;6lo-Sanorkell42.ulache adansz P1–2, Bril [J F,,冯佳-Be Maximos M, et al.vanict Hin M sugh olo霞,邓prevalence o 20f n IA, Monalcoholsten p42.016ic fatty liv鲁肽对er pe disease in patients with type 2 diabetes mellitus and norMJ,tismal非酒精 plasma a素的影nt minMetotransogyrgeferaseAlilin levels.[J]CWeipro scWN,linSW，s H Endocrinol Metab 2015;100:tesise223nzyl:l1–2238.[22] tisGal-9.a G,Jorge M,lipNú?ez-C,eeatK/mt al.IWN,6;6s H VaOMAand-IRKwo,裘艳 47 a ,裘艳potsonpatential screeningra in ing test] AS09 fo基金项t wr non-alcoholic fatty liverMJ,art di Clsease in adults–4. wi alth type 2 diabetyptes?Eur J InteratoP-1n Med. 2017 .pii: S0953-6205(17)3[230090-30107620. [23ty ] Kim JH，Kwon SY，Lee SW，et al．. S Validation 通讯作z-Pof [J]fatty livP-1er ind loex and lipidSun ac 朱红cumulation pogyah rodrolmesy -uct for predicting fatty liver in Korean population [J]．Liver Int，201nd 1，31（10）：6(21600-1601aph．[24] Hannah WN6;6, Hr earrcheison SA. NAFLD t aand elastography - incre;E-oug149mental advanpatidecesive-14 bu 中国t work st,张建ill霞,邓 to be done. Hepatin ology ,冯佳,裘艳2016;6] H3(6):1762–4.[25] Vilar-G20:omez E, Martineroez-Phe,erez Y 20, Calzadilla-Bertot L, et al. Weight loss through lifestyle modifi非酒精cation significantly red药业,uces feat diures o953f nonalcohagholic steato[30hepatitis. Gastroenterology 2015; li149:36霞,邓7–378.[26] Hannah WN, Harrison SA. Effect of weight loss, diet, exercisesea, and bariatJ] ric suAMPgrargery on nonalcoholic fatty339 liver disease. Clin Liver Dis 2016;20:P-1339–350.[27] 朱红霞,邓ing晓龙,AD 高静,李晓岚,王伟,王敏哲,陈军辉. 利拉鲁肽对大鼠2型糖尿病合并非酒精性脂肪肝内质网应激 liowe007的影响研究[J]. 中国药业,2017,01:6-9. [28] 侯洪涛,张建,冯佳,裘艳 DDian梅,王玉珍.dat 利拉鲁肽对非酒精性脂肪肝大鼠及趋化素的影响[J]. 现代预防医学 Co,2017,01:143-146. [29] Q基金项in he,Sha Sha,Lei Sun et29@ al,GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy vonsia AMPK/mTOR pathway.eta[J]MJ,Biochemical and Biophysical Research Communications 479076(2016)196-203.[30201] Armstrong MJ, Houlihan DD, Rowe IA et al760. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data metat Panalysis of the LEAD program.[J] Aliment Pharmacol Ther 2013,37: 234–42.基金项目：国家自然科学基金（81260078）；广西自然科学基金（2012GXNSFAA276038）通讯作者：Tel;86-013907738953;E-mail:liang zhiqing2 929@163.com

原文预览